Joint/commissioned bioequivalence testing policy has pros and cons

Some pharmaceutical companies are eagerly pursuing the independent conduct of bioequivalence testing to improve their global competitiveness.

But other companies said the controversial joint and/or commissioned bioequivalence testing system should exist to ensure less cost and quality in a collective manner.

The Korea Food and Drug Administration will announce its decision over the issue ...